Idarucizumab, a specific reversal agent for dabigatran: mode of action, pharmacokinetics and pharmacodynamics, and safety and efficacy in phase 1 subjects

MLA

Stephan Glund, et al. “Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 Subjects.” The American Journal of Emergency Medicine, vol. 34, Nov. 2016, pp. 26–32. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....6a2d1ae032403f0e266d75f0611cd87e&authtype=sso&custid=ns315887.

APA

Stephan Glund, Joanne van Ryn, Oliver Grottke, Paul A. Reilly, & Joachim Stangier. (2016). Idarucizumab, a specific reversal agent for dabigatran: mode of action, pharmacokinetics and pharmacodynamics, and safety and efficacy in phase 1 subjects. The American Journal of Emergency Medicine, 34, 26–32.

Chicago

Stephan Glund, Joanne van Ryn, Oliver Grottke, Paul A. Reilly, and Joachim Stangier. 2016. “Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 Subjects.” The American Journal of Emergency Medicine 34 (November): 26–32. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....6a2d1ae032403f0e266d75f0611cd87e&authtype=sso&custid=ns315887.